MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
10 Maio 2023 - 7:00AM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products and devices for patients with endocrine and
orphan lung diseases, announced today that its Chief Executive
Officer, Michael Castagna, PharmD, will participate in a Fireside
Chat at the 2023 RBC Capital Markets Global Healthcare Conference
on Tuesday, May 16, 2023 at 2:05 pm (ET) at the InterContinental
New York Barclay.
Interested parties can access a link to the webcast from the
News & Events section of the Company’s website at Events &
Presentations. The webcast replay will remain available for 14 days
following the live presentation.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development
and commercialization of innovative therapeutic products and
devices to address serious unmet medical needs for those living
with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and
device engineering prowess to lessen the burden of diseases such as
diabetes, pulmonary arterial hypertension (PAH) and nontuberculous
mycobacterial (NTM) lung disease. Our signature technologies –
dry-powder formulations and inhalation devices – offer rapid and
convenient delivery of medicines to the deep lung where they can
exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide,
we are on a mission to give people control of their health and the
freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on
LinkedIn, Facebook, Twitter or Instagram.
MannKind Contact:Rose Alinaya,
Investor Relations(818) 661-5000Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
MannKind (NASDAQ:MNKD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024